Navidea Biopharmaceuticals (NAVB) Tops Q1 EPS by 2c

Navidea Biopharmaceuticals (NYSE: NAVB) reported Q1 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $752 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Navidea Biopharmaceuticals (NAVB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter